Quoin Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: QNRX · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1671502
| Field | Detail |
|---|---|
| Company | Quoin Pharmaceuticals, Ltd. (QNRX) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing, shareholder-vote
Related Tickers: QNRX
TL;DR
Quoin Pharma (QNRX) filed an 8-K updating office location & reporting on shareholder votes. Nothing major flagged.
AI Summary
Quoin Pharmaceuticals, Ltd. filed an 8-K on April 9, 2024, reporting on matters submitted to a vote of security holders as of April 5, 2024. The filing indicates a change in the company's principal executive offices to Ashburn, VA, with a new phone number provided. The company was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
Why It Matters
This filing updates key corporate information, including executive office location and contact details, which is important for investors and stakeholders to have accurate and current information.
Risk Assessment
Risk Level: low — The filing is procedural and reports on standard corporate matters without indicating significant new risks or changes in business operations.
Key Players & Entities
- Quoin Pharmaceuticals, Ltd. (company) — Filer
- Cellect Biotechnology Ltd. (company) — Former company name
- Cellect Biomed Ltd. (company) — Former company name
- April 5, 2024 (date) — Date of earliest event reported
- April 9, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders as of April 5, 2024, and to update the company's principal executive offices and contact information.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 5, 2024.
What are the previous names of Quoin Pharmaceuticals, Ltd.?
Quoin Pharmaceuticals, Ltd. was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
Where are Quoin Pharmaceuticals, Ltd.'s principal executive offices now located?
Quoin Pharmaceuticals, Ltd.'s principal executive offices are now located at 42127 Pleasant Forest Court, Ashburn, VA 20148-7349.
What is the SEC file number for Quoin Pharmaceuticals, Ltd.?
The SEC file number for Quoin Pharmaceuticals, Ltd. is 001-37846.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-04-09 16:05:15
Filing Documents
- tm2411437d1_8k.htm (8-K) — 27KB
- 0001104659-24-045210.txt ( ) — 194KB
- qnrx-20240405.xsd (EX-101.SCH) — 3KB
- qnrx-20240405_lab.xml (EX-101.LAB) — 33KB
- qnrx-20240405_pre.xml (EX-101.PRE) — 22KB
- tm2411437d1_8k_htm.xml (XML) — 4KB
07. Submission
Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held a Special General Meeting of Shareholders (the "Special Meeting") on April 5, 2024. During the Special Meeting, shareholders were asked to consider and vote upon the following proposal: to approve the issuance of the maximum number of the Company's ordinary shares represented by ADSs issuable pursuant to the purchase agreement, dated as of January 25, 2024, with Alumni Capital LP (the "Alumni Issuance Proposal"). The shareholders approved the Alumni Issuance Proposal. The results of the voting for this proposal were as follows: For Against Abstain Broker Non-Votes 56,626 23,469 2,338 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: April 9, 2024 QUOIN PHARMACEUTICALS LTD. By: /s/ Gordon Dunn Name: Gordon Dunn Title: Chief Financial Officer